Keywords : paper, soft lithography, bio-functionnalisation, paper-based lab on chip
Paper-based microfluidic devices have enjoyed rapid development since Georges Whiteside1 introduced the mPADs concept. A series of hydrophilic/hydrophobic microstructures on paper substrates were fabricated to construct mPADs using a variety of processing techniques. Compared to conventional microfluidic chips made of glass and polymer substrates, mPADs possess many unique advantages including, low-cost, ease of fabrication, strong capillary action and good biological compatibility for applications in clinical diagnosis and environmental monitoring.
We develop some easy to use techniques to pattern smart paper with biomolecules and produce paper-based lab on chip.
Fig: Soft lithogrphy of Streptavidin patterns Alexa 790nm (yellow) et Alexa 680 nm (magenta) on paper.
1: Andres W. Martinez, Scott T. Phillips, and George M. Whitesides, Diagnostics for the Developing World: Microfluidic Paper-Based Analytical Devices, Anal. Chem. 2010, 82, 3–10
Microfluidic interface for microarray diagnostic
Keywords : microfluidics, reversible magnetic clamp, multiplexed immunoassay, allergen microarray
Reference: Reversible magnetic clamp of a microfluidic interface for the seric detection of food allergies on allergen microarrays, J. Foncy, E. Crestel, J-P Borges, A. Estève, J-C Cau, C. Vieu, L. Malaquin and E. Trévisiol, Microelectronic Engineering (2016).
To provide a robust platform for fluid handling, most microfluidic devices usually involve irreversible bonding methods to achieve a leak free interface between the microchannels and the holding substrate. Such an approach induces a major drawback when biological interactions are performed on a microarray format as it is difficult to recover the biochip for further fluorescence scanner analysis. This work describes an automated microfluidic platform using a reversible magnetic clamp for multiplexed immunodiagnostis. The microfluidic device is composed of a magnetic PDMS layer (containing iron powder) coated by PDMS, which is reversibly clamped to an epoxysilane glass slide containing an array of various antigens. The microfluidic device was validated for in vitro diagnosis of food allergies on an allergen microarray after serum interaction. The statistical analysis of spot intensities(Signal to noise ratios) on the microarray displayed excellent reproducibility. In addition to the reduction of volumes provided by miniaturization, this approach is versatile, easy-to- produce and provide an effective platform for multiplexed immunodiagnosis based on conventional fluorescent detection schemes.
Fig 1: Schematic view of the microfluidic device. Magnetic PDMS cartridge and the microarray are hold together by magnetic force using array of magnets under the device. a) Microfluidic cartridge composed by PDMS and a magnetic PDMS layer, b) microarray composed by an epoxysilane glass slide containing an array of various antigens (85 spots), c) the microfluidic cartridge and the microarray reversibly sealed by a magnetic field to ensure a conform and hermetic contact, d) section view of the device, e) View of the microfluidic interface.
Reversible magnetic clamp of a microfluidic interface and a glass slide spotted with a microarray of allergens for serum detection of food allergies
The PDMS microfluidic cartridge is transparent above the channels allowing optical imaging in the microfluidic device while the reversibility of the magnetic clamp allows the reading of the microarray after microfluidic removal using a conventional fluorescent scanner.
No leakage was observed below 150 mBar with the magnetic clamp.
The functionality of the device was validated for in vitro diagnosis of food allergies in the serum of a patient.
Fig 2: a) Microarray fluorescence image of the interacting spots after removal of the microfluidic reversible chip, b) signal to noise ratio quantification after food allergy immunodiagnostic using the microfluidic device. The patient was allergic to cow milk, coat milk and yolk eggs.
Low cost 2.0 diagnostics
For more than a decade labs-on-a-chip are described as ultimate tools for personalized healthcare and point-of-care diagnostics. Biosoft scientists agree with this affirmation and work on such a motivating topic. However it is clear that there is no such technology wide sprayed today due to technical and regulatory difficulties. Lab-on-a-chip will certainly be a reality tomorrow but today medical laboratories still use 1.0 methods or expensive 2.0 protocols.
While working on long-terms innovative diagnostics tools, Biosoft also develops a full chain of technological tools to manufacture a new generation of biochips, to manage a reliable interaction with serums and to analyze with simple instrumentation and efficient software solutions the biological response of the biochip.
Our aim is to adapt our available technologies to bring in no-time to the market a low-cost platform compliant with CE-IVD standard and targeting high potential applications for medical challenges. One of the best example is certainly the allergy detection. Prick tests are still widely used (clearly 1.0 methods) with the acknowledged risk of anaphylactic shock and the wide interdiction for food-allergic patients to eat a global family of aliments. More accurate tests are available but they are expensive and non-reimbursed by health systems. Low density biochips manufactured with our novel low-cost methods on a very small surface associated with a reliable management of simple fluidic systems and instrumentation based on conventional low-cost components is able to change habits in allergy detection. Such a low-cost biochip will bring personalize medicine to the allergy specialist and will deal with Prick tests, increasing security and accuracy.
Then low-cost 2.0 diagnostics are seen by Biosoft scientists as a bridge between conventional medicine and future wide-sprayed point-of-care tools. It should address the challenges of cost competitiveness with standard methods, enhancing reliability and accuracy, a fast transfer to the market, a regulatory compliance and an understanding of the needs of the medical staffs.